Fortis focuses on expanding the basic markets after the brand acquires

Fortis Healthcare, after obtaining permanent rights for its brand name for 200 rupees, has converted its focus on expanding operations through major hospital groups. The company is considering both Greenfield and Brownfield opportunities in the National Capital, Mumbai and Bangaluru area, with also preparing to add a new capacity in Punjab and building diagnostic work.

“We look at Greenfield and the opportunities for acquisition in NCR, Mumbai and Bengaluu”, “said Dr. Ashotosh Ragovanchi, Managing Director of Fortis Healthcare. “These are not new markets for us, but we explore options to deepen our existence – whether through developers’ partnerships or acquisition of operating hospitals that are in line with our strategy.”

The company is also incorporating its recent acquisition of the superior Hospital of Sheriman in Gallazhar in the current Punjab network, which includes hospitals in Ludiana, Emrertar and Mohaali. With running brownfield expansions, Fortis expects to reach about 2000 beds in the area.

Agilus Diagnostics, the Fortis Diagnostic arm, came through the brand transmission stage and is now expected to grow at a more stable pace. The company is working to expand its assembly network and opens new laboratories in genome and immunosuppress.

“We expect the diagnostic two numbers to appear next year,” said Dr. Raghuvanshi. “The new brand is now better, and we focus on improving operational efficiency and network scale.”

There is no immediate plan to include diagnostic work, but Dr. Raghuvanshi did not exclude her as soon as the work reaches performance levels closer to her peers in the industry.

On the hospital front, Fortis plans to deliver two new towers – in Noida and Faridabad facilities – adding about 200 beds in the early 26th year. There is a third tower in the MRI hospital in Gurugram is also on the right path to complete it by the end of the fiscal year.

The company continues to invest in digital systems. Its electronic medical records (EMR) are displayed in all hospitals, where EMRS already lives for external patients in 14 locations and the integration of internal patients under progress. The digital patient application, currently used for reservations, payments and records, is also linked to the EMR system.

“Digital channels now represent approximately 30 % of our patient’s flow. We expect the post over time with our EMR scales will increase through sites,” said Dr. Raghuvanshi.

Although Fortis has taken additional debts after the diagnostic acquisition, the debt ratio to the clear Ebitda is about 1.3. Dr. Raghuvanshi said that the company does not plan to collect immediate donations and expects its current expansion to be funded through internal dues. However, it is still open to raising the capital if the main acquisition is achieved.

“We continue to assess opportunities that provide value and fit them well with our current groups. Any decision to raise funds depends on the acquisition scale and its importance,” said CEO and CEO.

With the stability of the brand ownership, the hospital’s ability to grow, and improve the margins of diagnostic, Fortis moves to the 26th fiscal year with a focus on operating delivery and disciplined expansion. “We have also seen an increase in revenue from international patients, especially from Central Asia and Africa, even with the decrease in traffic from Bangladesh and the Middle East. We will closely monitor geopolitical factors, but we expect international contributions to remain fixed,” said Dr. Rajoviani.

Fortis Healthcare has registered 25.3 % growth year on an annual basis in EBITDA for the financial year ending in March 2025, driven by strong performance in the hospital sector and continued cost efficiency through the diagnostic arm. The company also announced the acquisition of the permanent rights of its commercial brand name for 200 rupees and recommended distributing $ 1 profit per share.

The total unified revenue increased by 12.9 % year on an annual basis to 7,783 rupees in the 25th fiscal year, while Ebitda grew to 1588 rupees with a margin of 20.4 %, an increase of 18.4 % in the previous year. The net profit after taxes and minority benefits increased by 29.3 % to 774 rupees.

In the last quarter of the fiscal year 25, revenues reached 2,007 rupees, an increase of 12.4 % over the same period last year. The Q4 operating EBITDA runs 14.3 % to 435 rupees. Fortis’s Diagnostics has recorded an increase in revenues by 4 % to 1,255 rupees in the fiscal year 25. EBITDA improved to 249 rupees, with margins to 19.8 % of 17.3 % last year. Modifying one -time brand expenses, EBITDA margins were 24.6 %.

Agilus conducted 39.2 million tests during the year, with a marginal increase of 38.8 million in the fiscal year 24. Preventive diagnoses constituted 11 % of the sector’s revenues. The company increased the points of its customers to 4,171 points and opened new laboratories focusing on genome and immunology. Fortis also strengthened its stake in Agilus to 89.2 % during the year, after acquiring 31.5 % of private stock investors.